P
169.80
5.71 (3.48%)
| 前收盘价格 | 164.09 |
| 收盘价格 | 163.07 |
| 成交量 | 1,740,748 |
| 平均成交量 (3个月) | 882,229 |
| 市值 | 4,246,217,984 |
| 价格/销量 (P/S) | 507.09 |
| 股市价格/股市净资产 (P/B) | 13.04 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业利益率 (TTM) | -2,868.84% |
| 稀释每股收益 (EPS TTM) | -10.66 |
| 季度收入增长率 (YOY) | 1,349.10% |
| 总债务/股东权益 (D/E MRQ) | 0.24% |
| 流动比率 (MRQ) | 8.44 |
| 营业现金流 (OCF TTM) | -163.91 M |
| 杠杆自由现金流 (LFCF TTM) | -90.04 M |
| 资产报酬率 (ROA TTM) | -39.95% |
| 股东权益报酬率 (ROE TTM) | -63.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Praxis Precision Medicines, Inc | 看涨 | 看涨 |
AIStockmoo 评分
-1.0
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.00 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 122.02% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 424.00 (BTIG, 149.71%) | 购买 |
| 中 | 317.00 (86.69%) | |
| 低 | 83.00 (Wedbush, -51.12%) | 卖出 |
| 83.00 (Jones Trading, -51.12%) | 购买 | |
| 平均值 | 285.40 (68.08%) | |
| 总计 | 9 购买, 1 卖出 | |
| 平均价格@调整类型 | 190.12 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Dec 2025 | 340.00 (100.24%) | 购买 | 247.99 |
| 25 Nov 2025 | 258.00 (51.94%) | 购买 | 184.25 | |
| Needham | 05 Dec 2025 | 304.00 (79.03%) | 购买 | 247.99 |
| 01 Dec 2025 | 250.00 (47.23%) | 购买 | 184.56 | |
| Wedbush | 05 Dec 2025 | 83.00 (-51.12%) | 卖出 | 247.99 |
| 06 Nov 2025 | 77.00 (-54.65%) | 卖出 | 172.35 | |
| BTIG | 19 Nov 2025 | 424.00 (149.71%) | 购买 | 189.32 |
| Chardan Capital | 17 Oct 2025 | 330.00 (94.35%) | 购买 | 189.99 |
| Deutsche Bank | 17 Oct 2025 | 280.00 (64.90%) | 购买 | 189.99 |
| Guggenheim | 17 Oct 2025 | 350.00 (106.12%) | 购买 | 189.99 |
| Truist Securities | 17 Oct 2025 | 360.00 (112.01%) | 购买 | 189.99 |
| Jefferies | 16 Oct 2025 | 300.00 (76.68%) | 购买 | 162.71 |
| Jones Trading | 18 Sep 2025 | 83.00 (-51.12%) | 购买 | 45.23 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合